Literature DB >> 21567091

27-hydroxycholesterol induces the transition of MCF7 cells into a mesenchymal phenotype.

Cristian G Torres1, María E Ramírez, Pamela Cruz, María J Epuñan, Luis E Valladares, Walter D Sierralta.   

Abstract

A decrease in the expression of E-cadherin and β-catenin, paralleling the loss of adherens junction complex, was observed in MCF7 cells exposed for longer than 48 h to 2 µM 27-hydroxycholesterol (27OHC), indicating an epithelial-mesenchymal transition (EMT). Upon removal of 27OHC from the culture medium, the cells released by the exposure of 72 h to the oxysterol grew as loosely packed cell groups. In these cells, accumulation of E-cadherin and β-catenin in the cytoplasm and the prolonged expression of epidermal growth factor receptor 2 (EGFR2/neu) in the plasma membrane were observed, suggesting that the acquired phenotype was related to the expression of this tyrosine kinase-growth factor receptor. The results presented here are discussed on the basis of the claimed relationship between 27OHC, hypercholesterolemia, macrophage infiltration and therapy-resistant ERα+ breast cancer incidence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21567091     DOI: 10.3892/or.2011.1284

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  15 in total

1.  Obesity, cholesterol metabolism, and breast cancer pathogenesis.

Authors:  Donald P McDonnell; Sunghee Park; Matthew T Goulet; Jeff Jasper; Suzanne E Wardell; Ching-Yi Chang; John D Norris; John R Guyton; Erik R Nelson
Journal:  Cancer Res       Date:  2014-07-24       Impact factor: 12.701

Review 2.  The significance of cholesterol and its metabolite, 27-hydroxycholesterol in breast cancer.

Authors:  Erik R Nelson
Journal:  Mol Cell Endocrinol       Date:  2017-09-15       Impact factor: 4.102

3.  Characterisation of a Mouse Model of Breast Cancer with Metabolic Syndrome.

Authors:  Linda A Buss; Anishah Mandani; Elisabeth Phillips; Nicola J A Scott; Margaret J Currie; Gabi U Dachs
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

Review 4.  The Role of Oxysterols in Human Cancer.

Authors:  Alzbeta Kloudova; F Peter Guengerich; Pavel Soucek
Journal:  Trends Endocrinol Metab       Date:  2017-04-12       Impact factor: 12.015

5.  The 14-3-3η/GSK-3β/β-catenin complex regulates EndMT induced by 27-hydroxycholesterol in HUVECs and promotes the migration of breast cancer cells.

Authors:  Jing Zhen; Kailin Jiao; Keke Yang; Maoxuan Wu; Qian Zhou; Bingmo Yang; Wei Xiao; Chunyan Hu; Ming Zhou; Zhong Li
Journal:  Cell Biol Toxicol       Date:  2020-11-01       Impact factor: 6.691

6.  Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor.

Authors:  Jia Gu; Neng Zhu; Hong-Fang Li; Tan-Jun Zhao; Chan-Juan Zhang; Duan-Fang Liao; Li Qin
Journal:  Cell Oncol (Dordr)       Date:  2022-07-22       Impact factor: 7.051

7.  27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression.

Authors:  Liqian Ma; Lawrence Wang; Adam T Nelson; Chaeyeon Han; Sisi He; Madeline A Henn; Karan Menon; Joy J Chen; Amy E Baek; Anna Vardanyan; Sayyed Hamed Shahoei; Sunghee Park; David J Shapiro; Som G Nanjappa; Erik R Nelson
Journal:  Cancer Lett       Date:  2020-08-28       Impact factor: 8.679

Review 8.  Impact of cholesterol-pathways on breast cancer development, a metabolic landscape.

Authors:  Alina González-Ortiz; Octavio Galindo-Hernández; Gerson N Hernández-Acevedo; Gustavo Hurtado-Ureta; Victor García-González
Journal:  J Cancer       Date:  2021-05-19       Impact factor: 4.207

9.  Hydroxysteroid sulfotransferase SULT2B1b promotes hepatocellular carcinoma cells proliferation in vitro and in vivo.

Authors:  Xiaoming Yang; Yali Xu; Fenghua Guo; Yanxia Ning; Xiuling Zhi; Lianhua Yin; Xiaobo Li
Journal:  PLoS One       Date:  2013-04-11       Impact factor: 3.240

Review 10.  Our evolving understanding of how 27-hydroxycholesterol influences cancer.

Authors:  Liqian Ma; Wonhwa Cho; Erik R Nelson
Journal:  Biochem Pharmacol       Date:  2021-05-24       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.